Non-small cell lung cancer

Active Ingredient: Bevacizumab

Indication for Bevacizumab

Population group: only adults (18 years old or older)
Therapeutic intent: Adjunct intent

Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

For this indication, competent medicine agencies globally authorize below treatments:

7.5 or 15 mg/kg of body weight once every 3 weeks


Dosage regimens

Regimen A: Intravenous, 7.5 milligrams bevacizumab, once every 3 weeks.

Regimen B: Intravenous, 15 milligrams bevacizumab, once every 3 weeks.

Detailed description

First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy

Bevacizumab is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by bevacizumab as a single agent until disease progression.

The recommended dose of bevacizumab is 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.

Clinical benefit in NSCLC patients has been demonstrated with both 7.5 mg/kg and 15 mg/kg doses. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.

Dosage considerations

It should not be administered as an intravenous push or bolus.

Dose reduction for adverse reactions is not recommended. If indicated, therapy should either be permanently discontinued or temporarily suspended.

Active ingredient


Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Read more about Bevacizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.